# Agenus Reports 48% Survival in Ovarian Cancer Trial

> Agenus shows 48% three-year survival for ovarian cancer patients with BOT+BAL combo after multiple treatments.
- Title: Agenus Reports 48% Survival in Ovarian Cancer Trial | Shortify
- Summary: Agenus shows 48% three-year survival for ovarian cancer patients with BOT+BAL combo after multiple treatments. Agenus' BOT+BAL combination achieved 48%…
- Keywords: agenus, bot, bal, ovarian cancer, recurrent ovarian cancer, igcs 2026, phase 1b trial, three-year survival, platinum-resistant, checkpoint immunotherapy, money, business
- Source: Financialpost — https://financialpost.com/pmn/business-wire-news-releases-pmn/agenus-reports-48-estimated-three-year-survival-with-botbal-in-recurrent-ovarian-cancer-at-igcs-2026
- Read time: 1 min
- Topics: agenus, bot, bal, ovarian cancer, recurrent ovarian cancer, igcs 2026, phase 1b trial, three-year survival, platinum-resistant, checkpoint immunotherapy, money, business
## Agenus Announces Ovarian Cancer Trial Results
Agenus Inc. reported three-year follow-up results from its Phase 1b C-800-01 trial for recurrent ovarian cancer patients.
## 48% Three-Year Survival Rate
Three-year overall survival remained at 48% for patients who received at least one dose of treatment.
## Heavily Pretreated Patient Population
Patients had received a median of four prior lines of therapy, with 66% having at least four treatments.
## Platinum-Resistant Disease Subset
Nearly three-quarters of patients had platinum-resistant or refractory ovarian cancer, meaning their cancer progressed during platinum treatment.
## Durable Clinical Benefit
The survival plateau suggests durable clinical benefit for patients who had already received multiple treatments.
## Dr. Porter's Perspective
Dana-Farber Cancer Institute's Dr. Rebecca L. Porter noted the survival plateau in heavily pretreated patients.

> What stands out with longer follow-up is the survival plateau in patients who had already received multiple treatments.
## BOT+BAL Combination Results
BOT+BAL achieved 23% objective response rate with one complete and seven partial responses.
## Long-Term Survival in Refractory Cases
Patients with platinum-resistant disease showed 47% three-year survival and 20% objective response rate.
## Treatment Strategy Implications
The results suggest BOT+BAL may be most effective before surgery to reduce recurrence and increase cure rates.
## Key takeaway

Agenus' BOT+BAL combination achieved 48% three-year survival in heavily pretreated ovarian cancer patients at IGCS 2026.